The Effect of Postoperative Naloxone in Certain Otolaryngologic Surgeries
Otolaryngology–Head and Neck Surgery · 2024
DOI: 10.1002/ohn.625 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, 2024. Written by Natalie M Perlov and 4 co-authors. Institution: Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Naloxone, Narcotic Antagonists, Otorhinolaryngologic Surgical Procedures, Postoperative Pain. 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIGMS NIH HHS.
Abstract (original language)
Objective
To evaluate the association of postoperative naloxone with the development of new substance use disorder (SUD), overdose, and death within 6 months of otolaryngologic surgery. Study Design Retrospective cohort database study on TriNetX.
Methods
Adult patients who underwent tonsil surgery (noncancerous), thyroid/parathyroid, septorhinoplasty, otology/neurotology, sinus/anterior skull base, and head and neck cancer surgeries between January 2003 and April 2023. Patients were excluded if they had an instance of SUD or overdose recorded in their charts prior to surgery, or had undergone another surgery within that 6‐month time frame. We hypothesized that patients prescribed naloxone postoperatively would have decreased odds for experiencing new SUD, overdose, and/or death within 6 months of surgery compared to patients who did not receive naloxone. P < .01 was considered statistically significant.
Results
There were 2,305,655 patients in this study. The average age was 36.7 ± 19.5 years old, with 46% female patients. Before matching, cohorts showed equivocal odds for developing new SUD, increased odds for overdose, and mixed odds for dying. After matching for demographic variables and comorbidities such as other substance use, opioid use for other pathologies, and psychiatric conditions, these effects diminished ( P > .01).
Conclusion
Our results suggest that postoperative naloxone may not significantly affect development of new SUD and incident overdose and death in certain otolaryngologic surgeries after controlling for prior SUD and psychiatric conditions. Clinicians should be aware of these comorbidities when considering their postoperative pain management protocol, which may or may not include naloxone.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Funding
- NIGMS NIH HHS
Cite
APA
Perlov, N. M., Shah, S. S., Bluj, J., Urdang, Z. D., & Chiffer, R. C. (2024). The Effect of Postoperative Naloxone in Certain Otolaryngologic Surgeries. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.625
Vancouver
Perlov NM, Shah SS, Bluj J, Urdang ZD, Chiffer RC. The Effect of Postoperative Naloxone in Certain Otolaryngologic Surgeries. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.625
BibTeX
@article{Perlov2024,
author = {Perlov, Natalie M and Shah, Sohan S and Bluj, Joann and Urdang, Zachary D and Chiffer, Rebecca C},
title = {The Effect of Postoperative Naloxone in Certain Otolaryngologic Surgeries},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2024},
doi = {10.1002/ohn.625}
}
EUVIMED